T-DXd with or without Avastin for HER2-low breast cancer that spread to the brain
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-low breast cancer (IHC 1+ or IHC 2+ with negative FISH/CISH).
- The cancer has spread to the brain (confirmed by MRI or CT) and you have at least one brain lesion that hasn't been radiated.
- You have not had more than 2 lines of chemotherapy for metastatic disease.
- You have never taken T-DXd (Enhertu) or bevacizumab (Avastin) before.
- You can have stable hormone therapy or mannitol for brain swelling if the dose hasn't gone up for at least a week.
- You are generally healthy enough for treatment (ECOG 0-1) and your organs are working well (adequate blood counts, liver & kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Hear when a new Breast Cancer With Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.